Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and nash. It has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases. The company was incorporated in 2009 and is based in Huddinge, Sweden.
तुलना करने के लिए मीट्रिक्स | SPRINT | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधSPRINTपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −8.9x | −3.0x | −0.5x | |
PEG अनुपात | 0.74 | −0.08 | 0.00 | |
क़ीमत/बुक | 37.8x | 2.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 4.6x | 4.8x | 3.3x | |
अपसाइड (विश्लेषक लक्ष्य) | 15.2% | 92.0% | 47.0% | |
उचित मूल्य अपसाइड | अनलॉक करें | 3.2% | 6.1% | अनलॉक करें |